The approval is based on the RELATIVITY-047 trial, which tested Opdivo + relatlimab against Opdivo monotherapy and had a PFS HR=0.75 (#msg-163914232).
In first-line melanoma, Opdulag offers comparable efficacy to Opdivo + Yervoy with less toxicity.
My abbreviated take:
$BMY's LAG-3 result in first-line melanoma looks like a fairly modest medical advance, but one that will probably make serious money for the company in the coming years. (I'm long.)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.